Evidence map›Paper›PMID 34539849›Full record

ArticleOncology letters2021

Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with

Jihyun Park, Hyejoo Park, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jihyun ParkCancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Hyejoo ParkCancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Ja Min ByunDepartment of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Junshik HongCancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Dong-Yeop ShinHematology Oncology Department, Center for Medical Innovation, Seoul National University Hospital, Seoul 03082, Republic of Korea.
Youngil KohCancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Sung-Soo YoonCancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Seoul National University · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in

Indexed as

acute myeloid leukemiacombined therapycytarabinemitogen-activated protein kinaseRAS

Identifiers

PMID34539849
PMCPMC8436357
OpenAlexW3193934226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.